Highlights Valneva

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 11/02/2026 GMT			5-day change	1st Jan Change
4.062 ^EUR	-2.54%		-2.64%	+9.25%

02-11	UK Regulator Issues New Restrictions for Valneva's Chikungunya Vaccine	MT
02-03	Global markets live: SpaceX, Tesla, Boeing, PayPal, AstraZeneca…

Highlights

02-11	UK Regulator Issues New Restrictions for Valneva's Chikungunya Vaccine	MT
02-03	Global markets live: SpaceX, Tesla, Boeing, PayPal, AstraZeneca…
02-03	Amundi, Publicis, Sartorius... Key Stocks to Watch Today in Paris
02-03	Valneva Se and Instituto Butantan Announce Initiation of Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine Ixchiq	CI
01-20	Wise and Virbac Benefit from Quarterly Results, Valneva and Logitech Slide
01-20	Valneva to Pull Regulatory Filings for Chikungunya Vaccine After US FDA Clinical Hold	MT
01-19	Valneva SE Provides Update on Chikungunya Vaccine IXCHIQ	CI
01-19	Valneva withdraws application for standard US approval of its chikungunya shot	RE
01-15	Expected Rise in Europe
01-12	Europe Expected to Open Flat Amid Concerns Over Fed Independence
01-06	The CAC 40 Recovers, DAX Closes at New Record High
01-01	Valneva, Serum Institute of India End Chikungunya Vaccine License Deal	MT
12-31	Valneva SE Terminates Vaccine Deal with Serum Institute	MT
12-31	Valneva SE and Serum Institute of India Announces Discontinuation of Chikungunya Vaccine License Agreement	CI
12-10	Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®	CI
11-26	Valneva SE Announces to Further Consolidate its Operations in France	CI
11-26	Valneva Se Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate	CI
11-20	Stifel Reiterates Buy Recommendation on Valneva
11-20	Valneva SE Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
11-20	Valneva Shares Rise Following Nine-Month Results
11-20	Valneva's cash, cash equivalents at EUR 143.5 mln at end-September	RE
11-20	Valneva SE Reiterates Earnings Guidance for the Year 2025	CI
11-04	Valneva SE Announces Positive Results of Its Phase 1 Clinical Trial Investigating the Safety and Immunogenicity of VLA1601	CI
11-04	Valneva reports positive results for Phase 1 trial of second-generation Zika vaccine candidate	RE
07/10/25	Valneva lowers financial forecasts for 2025

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Valneva: the return of biotech euphoria?

August 13, 2025 at 08:07 am